The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)
Status:
Completed
Trial end date:
2013-12-17
Target enrollment:
Participant gender:
Summary
Grazoprevir (MK-5172) and Elbasvir (MK-8742) were studied as the principal components of
combination oral therapy for hepatitis C virus (HCV). The study examined the pharmacokinetic
(PK) profiles of Grazoprevir and Elbasvir following 10 days of dosing in participants with
end stage renal disease (ESRD) on hemodialysis (HD) or participants with severe renal
impairment. Both groups were compared to healthy matched controls.